New peptides with metal binding abilities and their use as drug carriers.
暂无分享,去创建一个
Jean-Marie Pagès | J. Pagés | E. Galardon | I. Artaud | L. Maigre | Assia Hessani | Anas Allam | Laure Maigre | Mickael Alimi | Rodolphe Alves de Sousa | Assia Hessani | Erwan Galardon | Isabelle Artaud | R. Alves de Sousa | Mickael Alimi | A. Allam | Rodolphe Alves de Sousa
[1] L. Mercado,et al. Antimicrobial activity of trout hepcidin. , 2014, Fish & shellfish immunology.
[2] H. Nikaido,et al. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. , 2012, FEMS microbiology reviews.
[3] J. Cowan,et al. Target-directed catalytic metallodrugs , 2013, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[4] J. Pagés,et al. New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging. , 2013, ACS medicinal chemistry letters.
[5] Chris Orvig,et al. Metallodrugs in medicinal inorganic chemistry. , 2014, Chemical reviews.
[6] Trevor W. Hambley,et al. Metal-Based Therapeutics , 2007, Science.
[7] R. Hancock,et al. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.
[8] T. Hambley,et al. Cobalt complexes with tripodal ligands: implications for the design of drug chaperones. , 2012, Dalton transactions.
[9] L. Burrows,et al. The Efflux Inhibitor Phenylalanine-Arginine Beta-Naphthylamide (PAβN) Permeabilizes the Outer Membrane of Gram-Negative Bacteria , 2013, PloS one.
[10] P. Bispo,et al. Cation Concentration Variability of Four Distinct Mueller-Hinton Agar Brands Influences Polymyxin B Susceptibility Results , 2012, Journal of Clinical Microbiology.
[11] J. Svendsen,et al. The pharmacophore of short cationic antibacterial peptides. , 2003, Journal of medicinal chemistry.
[12] M. Winterhalter,et al. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria , 2008, Nature Reviews Microbiology.
[13] Anshika Sharma,et al. Peptide deformylase – a promising therapeutic target for tuberculosis and antibacterial drug discovery , 2009, Expert opinion on therapeutic targets.
[14] D. Knight,et al. Cobalt Complexes as Antiviral and Antibacterial Agents , 2010, Pharmaceuticals.
[15] J. Cowan,et al. Antimicrobial metallopeptides with broad nuclease and ribonuclease activity. , 2013, Chemical communications.
[16] V. Larue,et al. Discovery and refinement of a new structural class of potent peptide deformylase inhibitors. , 2007, Journal of medicinal chemistry.
[17] A. Casini,et al. Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. , 2013, Chemical Society reviews.
[18] J. Frère,et al. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. , 2008, The Lancet. Infectious diseases.
[19] T. Meinnel,et al. New Antibiotic Molecules: Bypassing the Membrane Barrier of Gram Negative Bacteria Increases the Activity of Peptide Deformylase Inhibitors , 2009, PloS one.
[20] S. Lippard,et al. Redox activation of metal-based prodrugs as a strategy for drug delivery. , 2012, Advanced drug delivery reviews.
[21] M. Ohmasa,et al. Characterization of Cobalt(III) Complexes with L-Penicillaminate. Crystal Structure of (Diethylenetriamine)(L-penicillaminato)cobalt(III) Chloride Monohydrate , 1982 .
[22] L. Washer,et al. Managing antimicrobial resistance in intensive care units , 2010, Critical care medicine.
[23] O. Mazarrasa,et al. High Concentrations of Manganese in Mueller-Hinton Agar Increase MICs of Tigecycline Determined by Etest , 2009, Journal of Clinical Microbiology.
[24] P. Dyson,et al. Metal-based antitumour drugs in the post-genomic era: what comes next? , 2011, Dalton transactions.
[25] T. Hambley,et al. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. , 2007, Chemistry.
[26] M. Zasloff. Antimicrobial peptides of multicellular organisms , 2002, Nature.
[27] Nicolas P E Barry,et al. Exploration of the medical periodic table: towards new targets. , 2013, Chemical communications.
[28] M. Berenbaum,et al. A method for testing for synergy with any number of agents. , 1978, The Journal of infectious diseases.
[29] H. Nikaido. Molecular Basis of Bacterial Outer Membrane Permeability Revisited , 2003, Microbiology and Molecular Biology Reviews.
[30] APPLICATION OF MASS SPECTROMETRIC TECHNIQUES TO THE DIFFERENTIATION OF PAINT MEDIA , 1972 .
[31] J. Pagés,et al. Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. , 1998, Microbiology.
[32] G. Anderegg,et al. Pyridinderivate als Komplexbildner. XI†. Die Thermodynamik der Metallkomplexbildung mit Bis-, Tris- und Tetrakis[(2-pyridyl)methyl]-aminen , 1977 .
[33] V. Larue,et al. New peptide deformylase inhibitors and cooperative interaction: a combination to improve antibacterial activity. , 2012, The Journal of antimicrobial chemotherapy.
[34] P. Roussel,et al. Characterization of cobalt(III) hydroxamic acid complexes based on a tris(2-pyridylmethyl)amine scaffold: reactivity toward cysteine methyl ester. , 2012, Inorganic chemistry.
[35] J. Flavin,et al. Combating multidrug-resistant Gram-negative bacterial infections , 2014, Expert opinion on investigational drugs.
[36] Trevor W. Hambley,et al. Cellular uptake and distribution of cobalt complexes of fluorescent ligands , 2008, JBIC Journal of Biological Inorganic Chemistry.
[37] J. Cervantes,et al. Improved Bioactivity of Antimicrobial Peptides by Addition of Amino‐Terminal Copper and Nickel (ATCUN) Binding Motifs , 2014, ChemMedChem.